Trial Outcomes & Findings for Cranial Cup Use for the Prevention of Positional Head Shape Deformity in the NICU (NCT NCT01218087)

NCT ID: NCT01218087

Last Updated: 2017-02-03

Results Overview

Cranial abnormality measurements were obtained at hospital discharge by orthotists blinded to the study group assignment. Cranial abnormalities include both cranial index measures and cranial symmetry measures. Cranial index (normal measurement between 73%-85%) was obtained dividing the head width (M-L) by length (A-P) then multiplying it by 100%. Cranial symmetry (normal measurement of\<8mm) was obtained by calculating the difference in the right and left anterior-posterior measures.

Recruitment status

TERMINATED

Study phase

NA

Target enrollment

88 participants

Primary outcome timeframe

up to 120 days

Results posted on

2017-02-03

Participant Flow

Approximately 800 infants from the 4 participating NICUs were screened; most were excluded for an anticipated length of stay of \< 14 days, for medical reasons, and a few parents declined. The total number enrolled out of the approximately 800 screened was 88.

Participant milestones

Participant milestones
Measure
Cranial Cup Device
The cranial cup device was used 12/24 hours and the moldable positioner device was used for positioning infants the remainder of the 24 hours.
Moldable Positioner Device
Moldable positioner device was used 24/24 hours as a comparison to the cranial cup and moldable positioner study arm.
Overall Study
STARTED
42
41
Overall Study
COMPLETED
27
35
Overall Study
NOT COMPLETED
15
6

Reasons for withdrawal

Reasons for withdrawal
Measure
Cranial Cup Device
The cranial cup device was used 12/24 hours and the moldable positioner device was used for positioning infants the remainder of the 24 hours.
Moldable Positioner Device
Moldable positioner device was used 24/24 hours as a comparison to the cranial cup and moldable positioner study arm.
Overall Study
Death
2
1
Overall Study
Withdrawal by Subject
5
0
Overall Study
Transferred
8
5

Baseline Characteristics

Cranial Cup Use for the Prevention of Positional Head Shape Deformity in the NICU

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Cranial Cup Device
n=27 Participants
cranial cup device: The cranial cup device was used 12/24 hours (alternating with the moldable positioner device) and was evaluated for feasibility, safety and efficacy for preventing head shape deformity in the infant
Moldable Positioner Device
n=35 Participants
moldable positioner device: This positioning device was used 24/24 hours as a comparison to the cranial cup device.
Total
n=62 Participants
Total of all reporting groups
Age, Continuous
0 days
n=5 Participants
0 days
n=7 Participants
0 days
n=5 Participants
Gender
Female
9 Participants
n=5 Participants
13 Participants
n=7 Participants
22 Participants
n=5 Participants
Gender
Male
18 Participants
n=5 Participants
22 Participants
n=7 Participants
40 Participants
n=5 Participants
Race/Ethnicity, Customized
White
15 participants
n=5 Participants
26 participants
n=7 Participants
41 participants
n=5 Participants
Race/Ethnicity, Customized
African American
7 participants
n=5 Participants
7 participants
n=7 Participants
14 participants
n=5 Participants
Race/Ethnicity, Customized
Asian
1 participants
n=5 Participants
0 participants
n=7 Participants
1 participants
n=5 Participants
Race/Ethnicity, Customized
Native Hawaiian
0 participants
n=5 Participants
1 participants
n=7 Participants
1 participants
n=5 Participants
Race/Ethnicity, Customized
Hispanic
4 participants
n=5 Participants
1 participants
n=7 Participants
5 participants
n=5 Participants
Region of Enrollment
United States
27 participants
n=5 Participants
35 participants
n=7 Participants
62 participants
n=5 Participants

PRIMARY outcome

Timeframe: up to 120 days

Cranial abnormality measurements were obtained at hospital discharge by orthotists blinded to the study group assignment. Cranial abnormalities include both cranial index measures and cranial symmetry measures. Cranial index (normal measurement between 73%-85%) was obtained dividing the head width (M-L) by length (A-P) then multiplying it by 100%. Cranial symmetry (normal measurement of\<8mm) was obtained by calculating the difference in the right and left anterior-posterior measures.

Outcome measures

Outcome measures
Measure
Cranial Cup Device
n=27 Participants
cranial cup device: The cranial cup device was used 12/24 hours (alternating with the moldable positioner device) and was evaluated for feasibility, safety and efficacy for preventing head shape deformity in the infant. Although infants in this arm did use the moldable positioner, they were analyzed separately from the comparison group.
Moldable Positioner Device
n=35 Participants
moldable positioner device: This positioning device was used 24/24 hours as a comparison to the cranial cup device.
Cranial Abnormalities Were Measured at Hospital Discharge
46 % participant cranial abnormalities
19 % participant cranial abnormalities

SECONDARY outcome

Timeframe: daily up to 120 days

daily log of cardiorespiratory events (apnea, bradycardia, oxygen desaturation) collected on a daily positioning log at the infant's bedside

Outcome measures

Outcome measures
Measure
Cranial Cup Device
n=27 Participants
cranial cup device: The cranial cup device was used 12/24 hours (alternating with the moldable positioner device) and was evaluated for feasibility, safety and efficacy for preventing head shape deformity in the infant. Although infants in this arm did use the moldable positioner, they were analyzed separately from the comparison group.
Moldable Positioner Device
n=35 Participants
moldable positioner device: This positioning device was used 24/24 hours as a comparison to the cranial cup device.
Incidence of Cardiorespiratory
5.4 cardioresp. events/100hrs of device use
5.9 cardioresp. events/100hrs of device use

Adverse Events

Cranial Cup Device

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Moldable Positioner Device

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Michele DeGrazia

Boston Children's Hospital

Phone: 617-919-1222

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place